Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Shares Issued (2017 - 2025)

Historic Shares Issued for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $583000.0.

  • Denali Therapeutics' Shares Issued changed N/A to $583000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 9896.12%. This contributed to the annual value of $499.3 million for FY2024, which is 270164.42% up from last year.
  • Per Denali Therapeutics' latest filing, its Shares Issued stood at $583000.0 for Q3 2025.
  • In the past 5 years, Denali Therapeutics' Shares Issued registered a high of $499.3 million during Q1 2024, and its lowest value of $583000.0 during Q3 2025.
  • Its 5-year average for Shares Issued is $52.4 million, with a median of $4.2 million in 2022.
  • Per our database at Business Quant, Denali Therapeutics' Shares Issued surged by 3102549.88% in 2024 and then plummeted by 9988.08% in 2025.
  • Quarter analysis of 5 years shows Denali Therapeutics' Shares Issued stood at $5.2 million in 2021, then skyrocketed by 5418.5% to $285.2 million in 2022, then tumbled by 98.35% to $4.7 million in 2023, then surged by 10511.12% to $499.3 million in 2024, then tumbled by 99.88% to $583000.0 in 2025.
  • Its last three reported values are $583000.0 in Q3 2025, $4.1 million for Q2 2025, and $595000.0 during Q1 2025.